March 11, 2014
1 min read

Hodgkin’s lymphoma treatment intensity linked to therapy-related AML/MDS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Intensity of treatment for Hodgkin’s lymphoma correlated with development of therapy-related acute myeloid leukemia and myelodysplastic syndrome, according to results of a retrospective study.

Allogeneic stem cell transplantation significantly improved outcomes of patients who developed the complication, researchers wrote.

Recent data regarding therapy-related AML and MDS after treatment for Hodgkin’s lymphoma are rare. Researchers conducted the current study to evaluate incidence, outcome and risk factors.

The analysis included 11,952 patients treated with newly diagnosed Hodgkin’s lymphoma who were enrolled in German Hodgkin Study Group trials from 1993 to 2009.

At median follow-up of 72 months, 106 patients (0.9%) developed therapy-related AML/MDS. The median time to occurrence was 31 months after Hodgkin’s lymphoma treatment. The median age of patients who developed therapy-related AML/MDS was older than that of the entire study population (43 years vs. 34 years; P<.0001).

Researchers determined patients who underwent four or more cycles of BEACOPP escalated chemotherapy during Hodgkin’s lymphoma treatment were at increased risk (1.7%) for treatment-related AML/MDS than those who underwent fewer than four cycles (0.7%) or those who did not undergo BEACOPP escalated (0.3%; P<.0001).

Researchers also evaluated outcomes of patients who developed treatment-related AML/MDS based on whether they underwent allogeneic stem cell transplantation. After median follow-up of 41 months, those who received ASCT demonstrated significantly longer median OS than those who did not (median not reached vs. 7.2 months; P<.001).

Disclosure: The researchers report no relevant financial disclosures.